|  | Baseline | 6 Months | 12 Months | p |
---|---|---|---|---|---|
Deferiprone | Â | Â | Â | Â | Â |
 | T2*, ms | 13.0 (32) | 15.4 (38) | 16.5 (38) | < 0.001 |
 | RVEDV, mL | 122.5 ± 24.9 | 123.2 ± 26.0 | 121.3 ± 24.9 | 0.61 |
 | RVESV, mL | 37.7 ± 11.7 | 35.9 ± 11.7 | 34.2 ± 11.3 | 0.009 |
 | RVSV, mL | 84.7 ± 16.5 | 87.3 ± 16.5 | 87.1 ± 17.0 | 0.16 |
 | RVEF, % | 69.6 ± 5.2 | 71.4 ± 4.7 | 72.2 ± 5.3 | 0.001 |
Deferoxamine | Â | Â | Â | Â | Â |
 | T2*, ms | 13.3 (30) | 14.4 (37) | 15 (39) | <0.001 |
 | RVEDV, mL | 124.7 ± 27.7 | 124.4 ± 26.2 | 128 ± 32.1 | 0.17 |
 | RVESV, mL | 38.1 ± 12.6 | 37.2 ± 12.5 | 39.1 ± 13.0 | 0.38 |
 | RVSV, mL | 86.7 ± 18.0 | 87.0 ± 15.5 | 88.9 ± 21.3 | 0.25 |
 | RVEF, % | 70.0 ± 5.8 | 70.8 ± 5.2 | 69.9 ± 4.6 | 0.93 |